Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enliven Therapeutics (ELVN) Interest & Investment Income (2019 - 2026)

Enliven Therapeutics has reported Interest & Investment Income over the past 8 years, most recently at $4.2 million for Q1 2026.

  • Quarterly results put Interest & Investment Income at $4.2 million for Q1 2026, up 31.29% from a year ago — trailing twelve months through Mar 2026 was $17.0 million (up 14.67% YoY), and the annual figure for FY2025 was $16.0 million, up 7.53%.
  • Interest & Investment Income reached $4.2 million in Q1 2026 per ELVN's latest filing, down from $4.6 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.9 million in Q3 2025 and bottomed at $9000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 5 years was $3.4 million (2023), compared with a mean of $2.8 million.
  • The largest annual shift saw Interest & Investment Income crashed 89.16% in 2022 before it soared 18722.22% in 2023.
  • Over 5 years, Interest & Investment Income stood at $613000.0 in 2022, then surged by 449.43% to $3.4 million in 2023, then grew by 10.33% to $3.7 million in 2024, then grew by 24.27% to $4.6 million in 2025, then fell by 9.14% to $4.2 million in 2026.
  • Business Quant data shows Interest & Investment Income for ELVN at $4.2 million in Q1 2026, $4.6 million in Q4 2025, and $4.9 million in Q3 2025.